CORALVILLE, Iowa, April 15, 2015 (GLOBE NEWSWIRE) -- KemPharm, Inc., a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary new molecular entity (NME) prodrugs, announced today the pricing of its initial public offering of 5,090,909 shares of its common stock at a price to the public of $11.00 per share. The shares are expected to begin trading on The NASDAQ Global Market under the ticker symbol "KMPH" on April 16, 2015. All of the common stock is being offered by KemPharm. In addition, KemPharm has granted the underwriters a 30-day option to purchase up to 763,636 additional shares of common stock from KemPharm. The offering is expected to close on April 21, 2015, subject to customary closing conditions.
Cowen and Company and RBC Capital Markets are acting as joint book-running managers for the offering. Canaccord Genuity and Oppenheimer & Co. are acting as co-managers.
A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on April 15, 2015. The offering is being made only by means of a prospectus. When available, copies of the final prospectus relating to this offering may be obtained by contacting: Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, Telephone: 631-274-2806, or RBC Capital Markets, Attention: Prospectus Department, 200 Vesey Street 8th Floor, New York, NY 10281, Telephone: 877-822-4089, Email: emailingequityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About KemPharm
KemPharm is a specialty pharmaceutical company focused on the discovery and development of NME prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high needs areas of pain, ADHD and other CNS disorders.
For KemPharm, Inc.: Gordon K. "Rusty" Johnson 319-665-2575 Media / Investor Contacts: Jason Rando / Joshua Drumm, Ph.D. Tiberend Strategic Advisors, Inc. 212-375-2665 / 2664
